Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2009

View Archived Issues

Additive antitumor activity seen with oncolytic measles virus and bevacizumab in glioma model

Schering-Plough presents novel gamma-secretase modulators for Alzheimer's disease

Shionogi presents NPY Y5 receptor antagonists for the treatment of obesity

(R)-Gossypol is safe and well tolerated in glioblastoma and lymphoma patients in phase II trials

ASCO snapshots: Agents investigated in leukemia, myelodysplasia

MKC-1 shows limited activity in platinum-resistant ovarian cancer

Mixed results seen with depsipeptide in radioiodine-refractory thyroid cancer

Schering-Plough discloses kinesin spindle protein inhibitors for cancer treatment

Nerviano Medical Sciences claims Aurora B kinase inhibitors for the treatment of cancer

Abbott describes vanilloid TRPV1 receptor antagonists for the treatment of pain

Oral L-arginine or L-citrulline improves endothelial dysfunction in heart failure outpatients

EMEA provides information on possible interaction between clopidogrel and PPIs

Lundbeck and Takeda report mixed results from phase III trials of Lu AA-21004 in MDD

Centocor signs 5-year CRADA with NCI to develop novel cell therapies to treat cancer

Elite and Epic have announced initial closing under March 2009 strategic alliance agreement

Johnson & Johnson initiates cash tender offer to acquire Cougar Biotechnology

Progenics discontinues development for PRO-206 in hepatitis C

StemCells reports phase I results for HuCNS-SC cells in Batten disease

FDA accepts for review Dyax's complete response submission for DX-88 in HAE

Kuros completes recruitment in phase IIb Kur-111 trial in tibial plateau fractures

Active Biotech completes enrollment in phase II TASQ study

Metabasis receives development event payment from Roche for MB-11362

PanGenetics receives approval for phase I anti-NGF antibody trial in chronic pain

Sinovac commences production of influenza A vaccine

CSL and Talecris mutually agree to terminate August 2008 merger agreement

Alder and Schering-Plough expand collaborative alliance agreement in monoclonal antibodies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...